Showing 1 - 20 results of 51 for search 'Mark R Litzow', query time: 0.06s Refine Results
  1. 1
    The increasing complexity of the management of core-binding factor acute myeloid leukemia

    The increasing complexity of the management of core-binding factor acute myeloid leukemia by Mark R. Litzow

    Published 2020-06-01
    Get full text
    Article
  2. 2
    The origins of the definition of complete remission in acute myeloid leukemia

    The origins of the definition of complete remission in acute myeloid leukemia by Mark R. Litzow

    Published 2025-02-01
    Get full text
    Article
  3. 3
    The real world of acute lymphoblastic leukemia

    The real world of acute lymphoblastic leukemia by Mark R. Litzow

    Published 2024-09-01
    Get full text
    Article
  4. 4
    Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia

    Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia by Tania Jain, Mark R. Litzow

    Published 2020-01-01
    Get full text
    Article
  5. 5
    Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets

    Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets by Pashtoon M. Kasi, Mark R. Litzow, Mrinal M. Patnaik, Shahrukh K. Hashmi, Naseema Gangat

    Published 2016-01-01
    Get full text
    Article
  6. 6
    Hepatotoxicity induced by arsenic trioxide: clinical features, mechanisms, preventive and potential therapeutic strategies

    Hepatotoxicity induced by arsenic trioxide: clinical features, mechanisms, preventive and potential therapeutic strategies by Jun Wen, Aiwen Li, Ziliang Wang, Xiaoxiao Guo, Gaoling Zhang, Mark R. Litzow, Qiuju Liu

    Published 2025-02-01
    Get full text
    Article
  7. 7
    Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor

    Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor by Margaret Nieborowska-Skorska, Elisabeth M. Paietta, Ross L. Levine, Hugo F. Fernandez, Martin S. Tallman, Mark R. Litzow, Tomasz Skorski

    Published 2019-12-01
    Get full text
    Article
  8. 8
    Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant

    Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant by Ayalew Tefferi, Animesh Pardanani, Kebede H. Begna, Aref Al-Kali, William J. Hogan, Mark R. Litzow, Rhett P. Ketterling, Kaaren K. Reichard, Naseema Gangat

    Published 2024-03-01
    Get full text
    Article
  9. 9
    Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases

    Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases by Maymona G. Abdelmagid, Mark R. Litzow, Kristen B. McCullough, Naseema Gangat, Animesh Pardanani, Hemant S. Murthy, James M. Foran, Rhett P. Ketterling, David Viswanatha, Kebede H. Begna, Ayalew Tefferi

    Published 2022-07-01
    Get full text
    Article
  10. 10
    Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy

    Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy by Naseema Gangat, Rimal Ilyas, Isla M Johnson, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek Mangaonkar, Mark R Litzow, William Hogan, Mithun Shah, Mrinal M Patnaik, Animesh Pardanani, Ayalew Tefferi

    Published 2023-03-01
    Get full text
    Article
  11. 11
    Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy

    Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy by Isla M. Johnson, Rimal Ilyas, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek Mangaonkar, Antoine Saliba, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

    Published 2025-02-01
    Get full text
    Article
  12. 12
    A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol

    A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG... by Neil D. Palmisiano, Ju‐Whei Lee, David F. Claxton, Elisabeth M. Paietta, Hassan Alkhateeb, Jae Park, Nikolai A. Podoltsev, Ehab L. Atallah, Dale G. Schaar, Shira N. Dinner, Jonathan A. Webster, Selina M. Luger, Mark R. Litzow

    Published 2024-10-01
    Get full text
    Article
  13. 13
    Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

    Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience by Ayalew Tefferi, Naseema Gangat, Mithun Shah, Hassan Alkhateeb, Mrinal S. Patnaik, Aref Al-Kali, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, Christopher C. Hook, Abhishek Mangaonkar, David Viswanatha, Dong Chen, Animesh Pardanani, Rhett P. Ketterling, Kebede H. Begna

    Published 2022-06-01
    Get full text
    Article
  14. 14
    U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity

    U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity by Talha Badar, Yenny A. Moreno Vanegas, Ahmad Nanaa, James M. Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B. Alkhateeb, David Viswanatha, Rong He, Mithun Shah, Cecilia Arana Yi, Mark R. Litzow, Naseema Gangat, Ayalew Tefferi, Mrinal M. Patnaik

    Published 2023-09-01
    Get full text
    Article
  15. 15
    Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900

    Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900 by Hugo F. Fernandez, Zhuoxin Sun, Mark R. Litzow, Selina M. Luger, Elisabeth Paietta, Janis Racevskis, Ross L. Levine, Jay P. Patel, Omar Abdel-Wahab, Rhett P. Ketterling, Gordon W. Dewald, John M. Bennett, Jacob M. Rowe, Hillard M. Lazarus, Martin S. Tallman

    Published 2019-04-01
    Get full text
    Article
  16. 16
    Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome

    Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome by Aref Al-Kali, Ahmad Nanaa, David Viswanatha, Rong He, Phuong Nguyen, Dragan Jevremovic, James M. Foran, Cecelia Arana Yi, Patricia T. Greipp, Naseema Gangat, Mrinal Patnaik, Ayalew Tefferi, Mark R. Litzow, Abhishek A. Mangaonkar, Mithun Vinod Shah, Talha Badar, Hassan B. Alkhateeb

    Published 2023-04-01
    Get full text
    Article
  17. 17
    Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma

    Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma by Ricardo D. Parrondo, Zaid Abdel Rahman, Michael G. Heckman, Mikolaj Wieczorek, Liuyan Jiang, Hassan B. Alkhateeb, Mark R. Litzow, Patricia Greipp, Taimur Sher, Leif Bergsagel, Rafael Fonseca, Vivek Roy, Angela Dispenzieri, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Sikander Ailawadhi, James M. Foran

    Published 2022-06-01
    Get full text
    Article
  18. 18
    Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms

    Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms by Talha Badar, Ahmad Nanaa, James M. Foran, David Viswanatha, Aref Al-Kali, Terra Lasho, Christy Finke, Hassan B Alkhateeb, Rong He, Naseema Gangat, Mithun Shah, Ayalew Tefferi, Abhishek A Mangaonkar, Mark R Litzow, Laura J. Ongie, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

    Published 2023-05-01
    Get full text
    Article
  19. 19
    Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms

    Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms by Mithun Vinod Shah, Abhishek A. Mangaonkar, Kebede H. Begna, Hassan B. Alkhateeb, Patricia Greipp, Ahmad Nanaa, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, Kristen McCullough, Ayalew Tefferi, Naseema Gangat, Mrinal M. Patnaik, Aref Al-Kali, Rong He, Dong Chen

    Published 2022-07-01
    Get full text
    Article
  20. 20
    The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

    The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia by John Barrett, Stephen J Forman, Jeffrey S Miller, Jill Brufsky, Jorge Cortes, Marcos de Lima, Michael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, Renier J Brentjens, Ephraim J Fuchs, Linda J Fukas, Steven D Gore, Mark R Litzow, John M Pagel, Martin S Tallman

    Published 2020-10-01
    Get full text
    Article

Search Tools: